Novo Nordisk A/S: all 1,444 studies

Page 15 of 15. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.

• Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia FracturesCompletedNCT00254514Phase 2
• Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal CombinationsCompletedNCT00184795Phase 3
• Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.CompletedNCT00184769Phase 4
• Efficacy on Height in SGA Children Treated With Growth HormoneCompletedNCT00184756Phase 3
• Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)CompletedNCT00184743Phase 3
• Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)CompletedNCT00184730Phase 3
• Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 YearsCompletedNCT00184691Phase 3
• Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone DeficiencyCompletedNCT00184678Phase 3
• Comparison of Insulin Detemir With NPH Insulin in Type 1 DiabetesCompletedNCT00184665Phase 3
• Growth Hormone Treatment in Adult Patients With Chronic Kidney DiseaseCompletedNCT00184652Phase 2
• Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 DiabetesCompletedNCT00184639Phase 3
• Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.CompletedNCT00184626Phase 4
• Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 DiabetesCompletedNCT00184613Phase 1
• Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 DiabetesCompletedNCT00184574Phase 3
• Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 DiabetesCompletedNCT00184561Phase 4
• Use of NovoSeven® in Active Variceal BleedingCompletedNCT00154492Phase 2
• Use of Activated Recombinant Human Factor VII in Cardiac SurgeryTerminatedNCT00154427Phase 2
• Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 DiabetesCompletedNCT00154414Phase 2
• Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedNCT00154401Phase 2
• Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and SyringeCompletedNCT00127296Phase 1
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00127283Phase 3
• Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain InjuryCompletedNCT00124293
• Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain InjuryCompletedNCT00123591Phase 2
• Novofine Autocover Safety Needle Versus BD Safety GlideCompletedNCT00121355Phase 4
• Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 DiabetesCompletedNCT00117780Phase 4
• A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion PumpCompletedNCT00115973Phase 1
• Vagifem Low Dose for Postmenopausal Atrophic Vaginitis SymptomsCompletedNCT00108849Phase 3
• Trial of NovoSeven® in Haemophilia - Joint BleedsCompletedNCT00108797Phase 4
• Efficacy of NovoSeven® in Bleeding Prophylaxis in HemophiliaCompletedNCT00108758Phase 2
• Comparison of Insulin Detemir With Insulin Glargine in Type 2 DiabetesCompletedNCT00106366Phase 3
• Dose Response to Recombinant Factor VIIa When Administered for BleedCompletedNCT00104455Phase 1
• Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 DiabetesCompletedNCT00104182Phase 3
• Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient ChildrenCompletedNCT00102817Phase 3
• Use of Activated Recombinant FVII in Spinal SurgeryCompletedNCT00102037Phase 2
• INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) StudyCompletedNCT00101751Phase 4
• Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 DiabetesCompletedNCT00097877Phase 3
• Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 DiabetesCompletedNCT00097279Phase 3
• Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 DiabetesCompletedNCT00097084Phase 3
• Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and AdolescentsCompletedNCT00097071Phase 3
• NovoLog Observation Trial in Subjects With Type 1 and Type 2 DiabetesCompletedNCT00095446Phase 4
• Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 DiabetesCompletedNCT00095082Phase 3
• Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric PopulationCompletedNCT00071448Phase 3
• Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational DiabetesCompletedNCT00065130Phase 3
• Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll DeficiencyCompletedNCT00056589Phase 1

← Novo Nordisk A/S overview and focus areas